[EN] INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS [FR] COMPOSÉS D'INDOLOQUINOLONE UTILISÉS EN TANT QU'INHIBITEURS DE KINASE DU LYMPHOME ANAPLASIQUE (ALK)
INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS
申请人:Jiangsu Ascentage Biomed Development Inc.
公开号:EP3110815A1
公开(公告)日:2017-01-04
US9783539B2
申请人:——
公开号:US9783539B2
公开(公告)日:2017-10-10
[EN] INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS<br/>[FR] COMPOSÉS D'INDOLOQUINOLONE UTILISÉS EN TANT QU'INHIBITEURS DE KINASE DU LYMPHOME ANAPLASIQUE (ALK)
申请人:JIANGSU ASCENTAGE BIOMED DEV INC
公开号:WO2015127629A1
公开(公告)日:2015-09-03
Disclosed herein are certain indoloquinolone compounds, methods of preparation thereof, pharmaceutical compositions thereof, and uses thereof, such as their uses as ALK inhibitors
公开了某些吲哚喹诺酮化合物、其制备方法、药物组合物及其用途,例如用作ALK抑制剂。
Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression
We report herein the discovery of a class of potent small-molecule inhibitors of anaplastic lymphoma kinase (ALK) containing a fused indoloquinoline scaffold. The most promising compound CJ-2360 has an IC50 value of 2.2 nM against wild-type ALK and low-nanomolar potency against several clinically reported ALK mutants. This compound is capable of achieving complete tumorregression in the ALK-positive